Clinical Trials
167 trialsNCT00869232 2026-05-22
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Active not recruiting
NCT00871013 2026-05-11
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
University of Arkansas
Phase 2 Active not recruiting
NCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT06530576 2025-11-18
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT03004287 2025-09-10
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
Phase 2 Active not recruiting
NCT02507336 2024-08-01
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
University of Miami
Phase 2 Completed
NCT04352205 2024-07-01
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
Phase 2 Terminated
NCT02586038 2024-05-08
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
University of Turin, Italy
Phase 2 Completed
NCT02891811 2024-03-29
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT06231680 2024-03-29
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Phase 2 Unknown
NCT00019539 2024-03-04
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00020046 2023-10-31
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00777998 2023-10-27
Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
UniversitƤtsklinikum Hamburg-Eppendorf
Phase 2 Completed
NCT04941937 2023-02-27
Selinexor in Combination With Immunomodulator ļ¼Thalidomide/Pomalidomide/Lenalidomideļ¼in RRMM
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT00014443 2023-01-09
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
Rush University Medical Center
Phase 2 Terminated
NCT00054158 2022-10-03
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
Roswell Park Cancer Institute
Phase 2 Completed
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT05266820 2022-03-18
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
NCT01125176 2022-01-21
ThRiL
Weill Medical College of Cornell University
Phase 2 Completed
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00025285 2021-09-09
Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00049361 2021-09-09
Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases
Wake Forest University Health Sciences
Phase 2 Completed
NCT00079092 2021-09-09
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
Wake Forest University Health Sciences
Phase 2 Completed
NCT00792142 2021-08-19
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT02128230 2021-06-22
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Terminated
NCT00538733 2021-05-24
T-BiRD
Weill Medical College of Cornell University
Phase 2 Completed
NCT04382300 2021-01-28
Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions
Shanghai Chest Hospital
Phase 2 Unknown
NCT00505635 2020-09-24
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00274820 2020-07-27
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00006890 2020-04-02
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
Phase 2 Completed
NCT02733380 2020-04-01
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT03608501 2020-01-14
IDEALL
Takeda
Phase 2 Withdrawn
NCT02410694 2019-12-13
Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT00049374 2019-10-17
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 2 Completed
NCT00025220 2019-07-23
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT03980002 2019-06-10
BDHCLL001
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT03062800 2019-06-05
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
Qilu Hospital of Shandong University
Phase 2 Unknown
NCT00179881 2019-02-05
Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 2 Completed
NCT00038181 2018-11-15
Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00400517 2018-08-28
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00310076 2018-08-23
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00064337 2018-08-09
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT00124579 2018-08-09
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Terminated
NCT00090870 2018-07-12
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT01779167 2018-07-11
THRiL for WM
Weill Medical College of Cornell University
Phase 2 Terminated
NCT01526694 2018-07-03
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
Azienda Ospedaliera di Bolzano
Phase 2 Completed
NCT00151281 2018-06-28
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
Weill Medical College of Cornell University
Phase 2 Completed
NCT00006358 2018-06-26
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed